These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20575235)

  • 1. Drug prices, out-of-pocket payments, and insurer costs: how do payers vary?
    Chen J; Rizzo JA
    Adv Health Econ Health Serv Res; 2010; 22():221-31. PubMed ID: 20575235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in Drug List Prices and Amounts Paid by Patients and Insurers.
    Yang EJ; Galan E; Thombley R; Lin A; Seo J; Tseng CW; Resneck JS; Bach PB; Dudley RA
    JAMA Netw Open; 2020 Dec; 3(12):e2028510. PubMed ID: 33295971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Reference Pricing for Diagnostic Laboratory Testing With Changes in Patient Choices, Prices, and Total Spending for Diagnostic Tests.
    Robinson JC; Whaley C; Brown TT
    JAMA Intern Med; 2016 Sep; 176(9):1353-9. PubMed ID: 27454826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Employer drug benefit plans and spending on prescription drugs.
    Joyce GF; Escarce JJ; Solomon MD; Goldman DP
    JAMA; 2002 Oct; 288(14):1733-9. PubMed ID: 12365957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical policies: effects of cap and co-payment on rational drug use.
    Austvoll-Dahlgren A; Aaserud M; Vist G; Ramsay C; Oxman AD; Sturm H; Kösters JP; Vernby A
    Cochrane Database Syst Rev; 2008 Jan; (1):CD007017. PubMed ID: 18254125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of costs of Medicare Part D prescriptions dispensed at retail and mail order pharmacies.
    Carroll NV
    J Manag Care Spec Pharm; 2014 Sep; 20(9):959-67. PubMed ID: 25166295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Market Power: Price Variation Among Commercial Insurers For Hospital Services.
    Bai G; Anderson GF
    Health Aff (Millwood); 2018 Oct; 37(10):1615-1622. PubMed ID: 30273037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicare Part D Payments for Topical Steroids: Rising Costs and Potential Savings.
    Song H; Adamson A; Mostaghimi A
    JAMA Dermatol; 2017 Aug; 153(8):755-759. PubMed ID: 28453645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hospital pricing: cost shifting and competition.
    Morrisey MA
    EBRI Issue Brief; 1993 May; (137):1-17. PubMed ID: 10129621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reference Pricing, Consumer Cost-Sharing, and Insurer Spending for Advanced Imaging Tests.
    Robinson JC; Whaley C; Brown TT
    Med Care; 2016 Dec; 54(12):1050-1055. PubMed ID: 27479594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer treatment cost in the United States: has the burden shifted over time?
    Tangka FK; Trogdon JG; Richardson LC; Howard D; Sabatino SA; Finkelstein EA
    Cancer; 2010 Jul; 116(14):3477-84. PubMed ID: 20564103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and projected patient and insurer costs for the care of patients with non-small cell lung cancer in the United States through 2040.
    Hess LM; Cui ZL; Wu Y; Fang Y; Gaynor PJ; Oton AB
    J Med Econ; 2017 Aug; 20(8):850-862. PubMed ID: 28532187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication Payments by Insurers and Patients for the Treatment of Metastatic Castrate-Resistant Prostate Cancer.
    Kaye DR; Lee HJ; Gordee A; George DJ; Ubel PA; Scales CD; Bundorf MK
    JCO Oncol Pract; 2023 Apr; 19(4):e600-e617. PubMed ID: 36689695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How important is price variation between health insurers?
    Craig SV; Ericson KM; Starc A
    J Health Econ; 2021 May; 77():102423. PubMed ID: 33838593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Describing out-of-pocket health payments in Chile: a look at two health care systems].
    Castillo-Laborde C; Villalobos Dintrans P
    Rev Med Chil; 2013 Nov; 141(11):1456-63. PubMed ID: 24718473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Price comparison of high-cost originator medicines in European countries.
    Vogler S; Zimmermann N; Babar ZU
    Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):221-230. PubMed ID: 27658050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why using current medications to select a medicare Part D plan may lead to higher out-of-pocket payments.
    Domino ME; Stearns SC; Norton EC; Yeh WS
    Med Care Res Rev; 2008 Feb; 65(1):114-26. PubMed ID: 17942795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Medicaid excess payments from alleged price manipulation of generic lorazepam.
    Bian B; Gorevski E; Kelton CM; Guo JJ; Martin Boone JE
    J Manag Care Pharm; 2012 Sep; 18(7):506-15. PubMed ID: 22971204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.